D5789BD0-2379-4E96-875F-0C72ED09B96D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.00131406044678
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.585
- ANGIOGENESIS+0.542
- NOTCH_SIGNALING+0.513
- INTERFERON_ALPHA_RESPONSE+0.453
- HEDGEHOG_SIGNALING+0.426
- MTORC1_SIGNALING+0.410
- OXIDATIVE_PHOSPHORYLATION+0.399
- INTERFERON_GAMMA_RESPONSE+0.387
- TGF_BETA_SIGNALING+0.387
- HYPOXIA+0.385
Top 10 suppressed
- KRAS_SIGNALING_DN-0.193
- SPERMATOGENESIS-0.108
- APICAL_SURFACE+0.009
- PI3K_AKT_MTOR_SIGNALING+0.010
- MYOGENESIS+0.067
- MITOTIC_SPINDLE+0.081
- WNT_BETA_CATENIN_SIGNALING+0.082
- HEME_METABOLISM+0.127
- APICAL_JUNCTION+0.149
- CHOLESTEROL_HOMEOSTASIS+0.152
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.943 |
| 2 | A7C71CEF-A5C7-4BAC-9090-9808B029190B | — | — | 0.920 |
| 3 | F5D36A14-8F2E-4C08-91BE-E3319784FF46 | — | — | 0.914 |
| 4 | CD273289-C865-4902-801B-E32CA866EB4B | — | — | 0.909 |
| 5 | 6ACB4FA8-1E5E-40FF-8C1F-980CF41215FB | — | — | 0.906 |
| 6 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.902 |
| 7 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.901 |
| 8 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.898 |
| 9 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.895 |
| 10 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 48 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.585 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.542 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.513 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.453 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.426 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.399 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.387 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.387 | Inavolisib | — uncovered |
| HYPOXIA | 0.385 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.363 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.361 | Inavolisib | — uncovered |
| APOPTOSIS | 0.345 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.343 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.334 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.333 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.328 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.328 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.328 | Inavolisib | — uncovered |